Comparative Pharmacology
Head-to-head clinical analysis: MYTREX F versus THIOSULFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTREX F versus THIOSULFIL.
MYTREX F vs THIOSULFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a corticosteroid that inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell activity.
Thiosulfil (sulfamethizole) is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis and thereby nucleic acid production.
Oral methotrexate 7.5-25 mg once weekly; subcutaneous methotrexate 7.5-25 mg once weekly; intravenous methotrexate 50-200 mg/m² every 2-3 weeks for oncology indications.
500 mg orally twice daily for 10-14 days.
None Documented
None Documented
3.5 hours (terminal); prolonged to 8-12 hours in renal impairment.
Terminal elimination half-life is 2-4 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Renal: 70-90% as unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic